PE20100257A1 - Sal glicinato de metformina como hipoglucemiante - Google Patents

Sal glicinato de metformina como hipoglucemiante

Info

Publication number
PE20100257A1
PE20100257A1 PE2009000908A PE2009000908A PE20100257A1 PE 20100257 A1 PE20100257 A1 PE 20100257A1 PE 2009000908 A PE2009000908 A PE 2009000908A PE 2009000908 A PE2009000908 A PE 2009000908A PE 20100257 A1 PE20100257 A1 PE 20100257A1
Authority
PE
Peru
Prior art keywords
ppm
hypoglycemiant
shows
spectrum
pmm
Prior art date
Application number
PE2009000908A
Other languages
English (en)
Inventor
Ochoa Jose Manuel Francisco Lara
Original Assignee
Silanes Sa De Cv Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40383805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20100257(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Silanes Sa De Cv Lab filed Critical Silanes Sa De Cv Lab
Publication of PE20100257A1 publication Critical patent/PE20100257A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UNA SAL DE METMORFINA Y GLICINA CARACTERIZADA PORQUE EL ESPECTRO DE RESONANCIA MAGNETICA NUCLEAR (RMN) DE PROTONES MUESTRA UN DESPLAZAMIENTO EN 2.814 PPM, 2.916 PMM, 4.677 PMM; UN ESPECTRO DE CARBONO 13 MUESTRA UN DESPLAZAMIENTO EN 37.754 PPM, 44.824 PPM, 158.761 PPM, 160.308 PPM Y 180.049 PPM Y UN ESPECTRO INFRERROJO (IR) PRESENTA SENALES DE ABSORCION EN 3367.34 CM-1, 3175.88 CM-1, 1618.78 CM-1 Y 1573.96 CM-1. TAMBIEN SE REFIERE A UN PROCESO DE PREPARACION PARA UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO MUESTRA UN EFECTO HIPOGLUCEMIANTE, SIENDO UTIL EN EL CONTROL DE GLUCOSA EN SANGRE
PE2009000908A 2008-06-26 2009-06-25 Sal glicinato de metformina como hipoglucemiante PE20100257A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/002665 WO2009144527A1 (en) 2008-06-26 2008-06-26 A new metformin glycinate salt for blood glucose control

Publications (1)

Publication Number Publication Date
PE20100257A1 true PE20100257A1 (es) 2010-04-10

Family

ID=40383805

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000908A PE20100257A1 (es) 2008-06-26 2009-06-25 Sal glicinato de metformina como hipoglucemiante

Country Status (26)

Country Link
US (2) US8703183B2 (es)
EP (1) EP2303838B1 (es)
JP (1) JP5551691B2 (es)
KR (1) KR101522066B1 (es)
CN (1) CN102159539B (es)
AR (1) AR074159A1 (es)
AU (1) AU2008357111B2 (es)
BR (1) BRPI0822909B8 (es)
CA (1) CA2729035C (es)
CL (1) CL2009001484A1 (es)
CY (1) CY1115098T1 (es)
DK (1) DK2303838T3 (es)
EC (1) ECSP10010719A (es)
ES (1) ES2450148T3 (es)
HR (1) HRP20140194T1 (es)
JO (1) JO2884B1 (es)
MA (1) MA32418B1 (es)
MX (1) MX2011000135A (es)
NI (1) NI201000234A (es)
PE (1) PE20100257A1 (es)
PL (1) PL2303838T3 (es)
PT (1) PT2303838E (es)
SI (1) SI2303838T1 (es)
TN (2) TN2010000604A1 (es)
UY (1) UY31945A (es)
WO (1) WO2009144527A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009144527A1 (en) 2008-06-26 2009-12-03 Laboratorios Silanes, S.A. De C.V. A new metformin glycinate salt for blood glucose control
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
CN103263405B (zh) * 2013-05-08 2015-04-22 南京医科大学 用于治疗糖尿病的药物组合物及其应用
US9815777B2 (en) 2013-09-22 2017-11-14 Jiva Pharma, Inc. Metformin salts to treat Type2 diabetes
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
EP3140316A1 (en) 2014-05-05 2017-03-15 Thetis Pharmaceuticals LLC Compositions and methods relating to ionic salts of peptides
WO2015183794A1 (en) * 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
WO2015195491A1 (en) 2014-06-18 2015-12-23 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of active agents
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
US9892234B2 (en) 2014-10-27 2018-02-13 Aseko, Inc. Subcutaneous outpatient management
CN105030745A (zh) * 2015-07-08 2015-11-11 南京医科大学 甘氨酸和二甲双胍的酰胺化产物在制备治疗糖尿病药物中的应用
EP3337402A4 (en) 2015-08-20 2019-04-24 Aseko, Inc. THERAPY ADVISER FOR THE MANAGEMENT OF DIABETES
EP3454907B1 (en) 2016-06-03 2020-07-22 Thetis Pharmaceuticals LLC Compositions and methods relating to salts of specialized pro-resolving mediators of inflammation
US11510886B2 (en) 2016-09-30 2022-11-29 Laboratorios Silanes, S.A. De C.V. Metformin amino acid compounds and methods of using the same
MX2019003725A (es) 2016-09-30 2019-08-12 Laboratorios Silanes S A De C V Glicinato de metformina, composiciones farmaceuticas que comprenden la misma, y metodos de uso de la misma.
CN113105367B (zh) * 2021-03-30 2022-08-02 广州大学 一类二甲双胍盐及其制备方法和应用
CN114349665B (zh) * 2021-11-30 2023-06-09 潍坊博创国际生物医药研究院 二甲双胍焦谷氨酸晶体及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE568513A (es)
FR2037002A1 (en) 1969-04-30 1970-12-31 Roques Bernard N-substd biguanide pamoic acid salts prepn
DE1967138A1 (de) 1969-07-17 1977-11-10 Christian Brunnengraeber Chem Therapeutisches mittel
AT325632B (de) 1973-06-01 1975-10-27 Hurka Wilhelm Verfahren zur herstellung von nicotinsauren salzen von derivaten des biguanids
FR2243684B1 (es) 1973-09-19 1977-01-28 Semb
CH602612A5 (es) 1974-10-11 1978-07-31 Hoffmann La Roche
FR2320735A1 (fr) 1975-08-12 1977-03-11 Dabis Georges Composition anti-cellulite
JPS57179494A (en) 1981-04-30 1982-11-05 Mitsubishi Plastics Ind Method of closing through hole of pipe, circumferential wall thereof has through hole in pipe axial direction
FR2585572B3 (fr) 1985-07-31 1987-12-31 Hugelin Andre Nouvelles compositions pharmaceutiques a base d'un sel de l'acide p. chlorophenoxyacetique destinees au traitement des neuropathies et assurant la regeneration nerveuse
PT793646E (pt) * 1994-11-23 2002-03-28 Biovitrum Ab Carboxilatos de aminoguanidina destinados ao tratamento de diabetes mellitus nao-insulinodependente
ES2216335T3 (es) 1997-12-08 2004-10-16 Bristol-Myers Squibb Company Nuevas sales de metformina y procedimiento.
US6936275B2 (en) 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
WO2003068209A1 (en) * 2002-02-14 2003-08-21 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
US7181457B2 (en) * 2003-05-28 2007-02-20 Pervasive Software, Inc. System and method for utilizing compression in database caches to facilitate access to database information
EP1677758A1 (en) 2003-10-31 2006-07-12 ALZA Corporation Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid
WO2005065675A1 (en) 2004-01-07 2005-07-21 Premacs International Pty. Ltd. Method of treatment
WO2006086856A1 (en) * 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
CN101180073A (zh) * 2005-04-27 2008-05-14 贾拉尔·梅萨德克 胰岛素组合
US7973073B2 (en) * 2006-06-16 2011-07-05 Indigene Pharmaceuticals, Inc. Antidiabetic agent for control of diabetic hyperglycemia and diabetic complications
NZ556735A (en) * 2007-07-24 2009-03-31 Vector Ltd Securing devices and equipotential bonding system
WO2009144527A1 (en) 2008-06-26 2009-12-03 Laboratorios Silanes, S.A. De C.V. A new metformin glycinate salt for blood glucose control

Also Published As

Publication number Publication date
BRPI0822909B8 (pt) 2021-05-25
MX2011000135A (es) 2011-02-25
KR101522066B1 (ko) 2015-05-20
NI201000234A (es) 2012-03-19
CY1115098T1 (el) 2016-12-14
HRP20140194T1 (hr) 2014-06-20
AU2008357111B2 (en) 2013-05-09
PL2303838T3 (pl) 2014-07-31
JP5551691B2 (ja) 2014-07-16
BRPI0822909B1 (pt) 2019-11-12
CL2009001484A1 (es) 2009-12-04
ES2450148T3 (es) 2014-03-24
CN102159539A (zh) 2011-08-17
CN102159539B (zh) 2014-04-16
JP2011525900A (ja) 2011-09-29
UY31945A (es) 2010-01-05
EP2303838A1 (en) 2011-04-06
US8703183B2 (en) 2014-04-22
DK2303838T3 (en) 2014-03-03
WO2009144527A1 (en) 2009-12-03
AR074159A1 (es) 2010-12-29
CA2729035A1 (en) 2009-12-03
AU2008357111A1 (en) 2009-12-03
PT2303838E (pt) 2014-03-10
USRE46496E1 (en) 2017-08-01
BRPI0822909A2 (pt) 2015-06-30
SI2303838T1 (sl) 2014-07-31
TN2010000604A1 (en) 2012-05-24
KR20110042165A (ko) 2011-04-25
CA2729035C (en) 2015-10-20
MA32418B1 (fr) 2011-06-01
TN2010000607A1 (en) 2012-05-24
JO2884B1 (en) 2015-03-15
EP2303838B1 (en) 2013-12-04
US20110171142A1 (en) 2011-07-14
ECSP10010719A (es) 2011-01-31

Similar Documents

Publication Publication Date Title
PE20100257A1 (es) Sal glicinato de metformina como hipoglucemiante
CL2013000716A1 (es) Un profarmaco o una sal del mismo que comprende un conjugado de exendina-conector; procedimiento de preparacion de dicho profarmaco; compuestos intermediarios; composicion farmaceutica que lo comprende, util para mejorar el control glucemico en pacientes con diabetes de tipo 2.
NL300943I2 (nl) Ertugliflozine, desgewenst in kristalvorm, met name als co-kristal met L-pyroglutaminezuur, met name Ertugliflozin L-pyroglutamine zuur
BRPI0919946A2 (pt) tratamento de diabetes melito usando injeções de insulina com frequência de injeção menor que diariamente
CO6210752A2 (es) Compuestos biciclicos y uso como antidiabeticos
NI201200013A (es) Composición de insulina de acción prolongada
NZ609309A (en) Redox drug derivatives
MX2015016303A (es) Uso de derivados del acido tetramico como nematicidas.
WO2011008823A3 (en) Peptide-mediated non-covalent delivery of active agents across the blood brain barrier
MX2014002159A (es) Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
HK1162023A1 (en) Gpr120 receptor agonists and uses thereof gpr120
NZ598085A (en) Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid
BRPI0517701A8 (pt) métodos de tratamento de diabetes mellitus
BR112012012903A2 (pt) compostos de espiropiperidina
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
PH12015501931B1 (en) Treatment of diabetes mellitus by long-acting formulations of insulins
EA201070250A1 (ru) Противомикробный парентеральный состав
ES2673406T3 (es) Alfa-derivados de ácidos grasos cis-monoinsaturados para uso como medicamentos en el tratamiento de la diabetes
ECSP11010927A (es) Uso de análogos de ácidos heteroaromáticos que contienen azufre
WO2013155528A3 (en) Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels
WO2013063412A3 (en) Methods of diagnosis and treatment of endoplasmic reticulum (er) stress-related conditions
PH12014501646A1 (en) Substituted phenylazole derivative
CO6310997A2 (es) Derivados de arilpirazinona como estimulantes de la secrecion de insulina metodos para obtenerlos y uso para el tratamiento de diabetes
WO2011000945A3 (en) Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns

Legal Events

Date Code Title Description
FG Grant, registration